Gilead Sciences has signed non-exclusive, licensing agreement with five generic manufacturers to expand access to its experimental antiviral drug remdesivir for Covid-19 patients.
The licensees include Mylan, Cipla, Hetero Labs and Jubilant Life Sciences in India, as well as Ferozsons Laboratories in Pakistan.
The companies will be able to manufacture and distribute remdesivir in 127 countries. According to Gilead, remdesivir will be made available in low, lower-middle, upper-middle and high-income countries, reported Reuters.
India, Pakistan, Afghanistan, North Korea and South Africa are among the countries set to receive the drug. The licensees can set their own prices for the generic version they manufacture.